PPBT Key Statistics, Chart & Performance
The current stock price of PPBT is 0.822 USD. In the past month the price increased by 4.18%. In the past year, price decreased by -78.54%.
PPBT Latest News, Press Relases and Analysis
PPBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.9 | 954.25B | ||
| JNJ | JOHNSON & JOHNSON | 20.23 | 505.98B | ||
| MRK | MERCK & CO. INC. | 11.24 | 245.74B | ||
| PFE | PFIZER INC | 8.06 | 146.69B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.8 | 104.23B | ||
| ZTS | ZOETIS INC | 18.56 | 51.85B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.44 | 22.40B | ||
| VTRS | VIATRIS INC | 4.97 | 13.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.16 | 10.57B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.01 | 9.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.24B |
Related stock screener links
About PPBT
Company Profile
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Company Info
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104 IL
CEO: Gil Efron
Employees: 9
Phone: 97239333121
PURPLE BIOTECH LTD-ADR / PPBT FAQ
Can you describe the business of PURPLE BIOTECH LTD-ADR?
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Can you provide the latest stock price for PURPLE BIOTECH LTD-ADR?
The current stock price of PPBT is 0.822 USD. The price decreased by -0.45% in the last trading session.
Does PURPLE BIOTECH LTD-ADR pay dividends?
PPBT does not pay a dividend.
What is the ChartMill rating of PURPLE BIOTECH LTD-ADR stock?
PPBT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is PPBT stock listed?
PPBT stock is listed on the Nasdaq exchange.
How is the valuation of PURPLE BIOTECH LTD-ADR (PPBT) based on its PE ratio?
PURPLE BIOTECH LTD-ADR (PPBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
What is the market capitalization of PPBT stock?
PURPLE BIOTECH LTD-ADR (PPBT) has a market capitalization of 7.42M USD. This makes PPBT a Nano Cap stock.
PPBT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PPBT. When comparing the yearly performance of all stocks, PPBT is a bad performer in the overall market: 83.9% of all stocks are doing better.
PPBT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PPBT. PPBT has a bad profitability rating. Also its financial health evaluation is rather negative.
PPBT Financial Highlights
Over the last trailing twelve months PPBT reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 85.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.32% | ||
| ROE | -9.92% | ||
| Debt/Equity | 0 |